grant
Expanding the cancer paralog genetic interaction map to enable precision oncology
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2026AcuteAnti-Cancer AgentsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsAssayAutomobile DrivingBioassayBiological AssayBiological MarkersBlind SpotsCRISPRCRISPR approachCRISPR based approachCRISPR editing screenCRISPR methodCRISPR methodologyCRISPR screenCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based screenCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas systemCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 screenCRISPR/Cas9 technologyCancer CauseCancer DrugCancer EtiologyCancer PatientCancer TreatmentCancersCas nuclease technologyCell BodyCell LineCellLineCellsCessation of lifeCheckpoint inhibitorClustered Regularly Interspaced Short Palindromic RepeatsClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCollaborationsComputational BiologyComputer softwareDNA mutationDataData ScienceDeathDependenceDevelopmentDrug TargetingDrug resistanceDrugsEGF ReceptorEGFRERBB ProteinEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsGene DuplicationGene FamilyGene TranscriptionGeneralized GrowthGenesGeneticGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenomeGenomicsGrowthGuide RNAHER1HumanHuman GenomeImmune checkpoint inhibitorImmune mediated therapyImmunologically Directed TherapyImmunotherapyKnock-outKnockoutLytotoxicityMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMapsMedicationMethodsModern ManMutationNSCLCNSCLC - Non-Small Cell Lung CancerNeoplastic Disease Chemotherapeutic AgentsNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOncogenesisPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPharmaceutical PreparationsPulmonary CancerPulmonary malignant NeoplasmRNA ExpressionReproducibilityResistanceRetinal blind spotSoftwareSpecificityStrains Cell LinesSurvival RateTGF-alpha ReceptorTherapeuticTissue GrowthTranscriptionTransforming Growth Factor alpha ReceptorTumor-Specific Treatment AgentsUrogastrone ReceptorValidationWorkacquired drug resistanceanti-cancer druganti-cancer therapybio-markersbiologic markerbiomarkerc-erbB-1c-erbB-1 Proteincancer cellcancer therapycancer-directed therapycell typechemotherapyclustered regularly interspaced short palindromic repeats screencomputer biologycultured cell linecytotoxicitydevelop drug resistancedevelopmentaldrivingdrug resistance developmentdrug resistantdrug/agentdruggable targeterbB-1erbB-1 Proto-Oncogene ProteinerbBlfunctional genomicsgRNAgene functiongenome mutationgenome scalegenome-widegenomewidehuman whole genomeimmune check point inhibitorimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedin vivoindividualized cancer careindividualized oncologyinhibitorinnovateinnovationinnovativeinteractive data visualizationinteractive visualizationinternet portalknockout geneloss of functionlung cancermalignancyneoplasm/cancernew anti-cancer agentnew anticancer agentnew anticancer drugnew antineoplasticnew approachesnew cancer drugnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeutic targetnew therapeuticsnew therapynew therapy approachesnew therapy targetnew treatment approachnew treatment strategynext generation therapeuticsnovel anti-cancer agentnovel anti-cancer drugnovel anticancer agentnovel anticancer drugnovel antineoplasticnovel approachesnovel cancer drugnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy approachnovel therapy targeton-line portalonline portalontogenyparalogparalogous genepatient oriented outcomespersonalized oncologypre-clinicalpre-clinical developmentpre-clinical efficacyprecision cancer careprecision cancer medicineprecision oncologypreclinicalpreclinical developmentpreclinical efficacypreventpreventingproto-oncogene protein c-erbB-1resistance to Drugresistantresistant to DrugscRNA sequencingscRNA-seqscreeningscreeningssingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsuccesssynthetic lethal interactionsynthetic lethalitytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttranslational medicinetumortumor growthtumorigenesisvalidationsweb portalweb-based portal
Description preview
PROJECT SUMMARY/ABSTRACT
Recent advances in targeted therapies have prolonged the survival of non-small cell lung cancer patients.
However, lung cancer still remains the leading cause of cancer deaths in the U.S. and worldwide, and the 5-year
survival rate for non-small cell lung cancer is a dismal 24%. For many tumors, drug-targetable mutations…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click